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Abstract 13 
In oral delivery, lag phases of programmable duration that precede drug release may 14 
be advantageous in a number of instances, e.g. to meet chronotherapeutic needs or 15 
pursue colonic delivery. Systems that give rise to characteristic lag phases in their 16 
release profiles, i.e. intended for time-controlled release, are generally composed of a 17 
drug-containing core and a functional polymeric barrier. According to the nature of the 18 
polymer, the latter may delay the onset of drug release by acting as a rupturable, 19 
permeable or erodible boundary layer. Erodible systems are mostly based on water 20 
swellable polymers, such as hydrophilic cellulose ethers, and the release of the 21 
incorporated drug is deferred through the progressive hydration and erosion of the 22 
polymeric barrier upon contact with aqueous fluids. The extent of delay depends on the 23 
employed polymer, particularly on its viscosity grade, and on the thickness of the layer 24 
applied. The manufacturing technique may also have an impact on the performance of 25 
such systems. Double-compression and spray-coating have mainly been used, resulting 26 
in differing technical issues and release outcomes. In this article, an update on delivery 27 
systems based on erodible polymer barriers (coatings, shells) for time-controlled release 28 
is presented. 29 
 30 
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Introduction 35 
Oral delivery systems for time-controlled release are able to defer the onset of drug 36 
release into the gastrointestinal tract for a programmable lag period independent of pH, 37 
ionic strength, enzyme concentration and other physiological parameters. It is by now 38 
recognized that a delay prior to release may be advantageous for effective 39 
pharmacological treatment of several pathologic conditions [1]. This is typically the 40 
case with a variety of high-morbidity rheumatic, cardiovascular and respiratory chronic 41 
diseases, which show cyclic patterns in their signs and symptoms [1,2]. When these 42 
mainly recur at night or in the early morning hours, bedtime administration of drug 43 
products having a proper lag phase in their release profile would help provide 44 
pharmacological protection as needed. On the other hand, both untimely awakenings, as 45 
an immediate-release dosage form would require, and exposure to unnecessarily 46 
sustained therapeutic drug levels, as prolonged-release formulations taken before sleep 47 
would entail, could thereby be overcome. As a result, not only the efficacy and safety of 48 
a treatment but also the relevant patient compliance may greatly be enhanced through 49 
the use of chronopharmaceutical delivery systems. 50 
Besides, a lag phase prior to release allows to target the colonic region with drug 51 
molecules intended for either a local action, e.g. to treat Inflammatory Bowel Disease 52 
(IBD), or for systemic absorption, especially of biotech molecules that pose stability 53 
issues in the proximal gut and may benefit from the aid of enhancers for mucosal 54 
permeation [3,4]. When colon delivery is sought, the lag phase is expected to last 55 
throughout the entire small intestinal transit (3 h ± 1 SD), which was reported not to be 56 
strongly influenced by the characteristics of dosage units and by food intake [5,6]. 57 
Moreover, the lag period should be started upon emptying from the stomach rather than 58 
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on administration, owing to the high variability of gastric residence that cannot reliably 59 
be predicted. Hence, in order to attain colonic release based on a time-controlled 60 
approach, enteric coating is generally required. 61 
Repeated lag phases, each followed by the release of a drug dose fraction, may be 62 
exploited to fulfill multiple daily administrations regimens when prolonged release is 63 
not a viable option, e.g. because of pharmacokinetic (strong first-pass effect) or 64 
pharmacodynamic (tolerance) constraints. Successive release pulses are also proposed 65 
as an alternative strategy in antibiotic therapy, possibly resulting in restrained growth of 66 
resistant bacterial strains [7]. 67 
Finally, properly modulated lag phases prior to the release of co-administered 68 
bioactive compounds may avoid undesired drug-drug interactions in the gastrointestinal 69 
tract and overcome the need for differing dosing schedules, thus improving the overall 70 
patient convenience and compliance [8]. 71 
Peroral delivery systems for time-controlled release are expected to yield lag phases 72 
on the order of few hours, which may be consistent with their mean residence time 73 
within the digestive tract. These are often pursued through functional polymeric barriers 74 
that enclose an inner drug formulation [9,10]. According to the physico-chemical 75 
properties of their polymeric components and type of excipients added (plasticizers, 76 
pore formers, bulking agents), such barriers delay the onset of release via differing 77 
mechanisms. They may indeed undergo time-programmed disruption, become leaky or 78 
be subject to progressive erosion/dissolution. In particular, erodible systems are 79 
generally single-unit dosage forms based on a drug containing-core, such as an 80 
immediate-release tablet or capsule, and a swellable hydrophilic barrier of adequate 81 
thickness and polymer viscosity. Such a barrier may be a coating or, in more recent and 82 
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innovative instances, a freestanding release-modifying shell available for filling with 83 
any drug formulation. 84 
Because of the inherent safety and biocompatibility profile as well as of their 85 
availability in a range of grades and reasonable costs, hydrophilic cellulose derivatives, 86 
namely hydroxypropyl methylcellulose (HPMC) and, less frequently, hydroxypropyl 87 
cellulose (HPC) and hydroxyethyl cellulose (HEC), are broadly used as the functional 88 
polymers in erodible delivery systems [11]. Other polysaccharides, including 89 
galactomannans, alginates, xanthan gum, and non-saccharide hydrophilic polymers, 90 
such as polyvinyl alcohol (PVA) and polyethylene oxide (PEO), are nonetheless also 91 
employed. All of these materials are largely utilized in the food, pharmaceutical, 92 
nutraceutical and cosmetic industries mainly as rheology-modifiers, stabilizers, binders 93 
and film-coating agents. 94 
Upon water uptake, such polymers typically go through a glassy-rubbery 95 
thermodynamic transition that is associated with distension and disentanglement of their 96 
macromolecular chains [12-14]. Consequently, the polymer structure may expand, erode 97 
due to mechanical attrition and/or dissolve at a rate that chiefly depends on the relevant 98 
physico-chemical characteristics and on the ionic strength and temperature of the 99 
medium. As the aqueous fluid penetrates into the polymeric layer, a swelling front, i.e. 100 
the boundary between the glassy and the rubbery domain, and an erosion front, at the 101 
interface between the rubbery polymer and the outer medium, are identified. Depending 102 
on the relative movements of the swelling and erosion fronts, which in turn are 103 
governed by the hydration, dissolution and viscosity properties of the polymer, a gel 104 
layer of varying thickness is formed. 105 
6 
 
In a few instances, insoluble materials are added to the hydrophilic polymers to 106 
modulate the degree of hydration of the barrier, or even used as the main components of 107 
mechanically erodible coatings. In the latter case, their erosion in aqueous fluids would 108 
need to be promoted by surfactant excipients. 109 
Drug release from hydrophilic erodible systems is in principle deferred until the 110 
entire polymeric layer is in the swollen state, i.e. when the swelling front has reached 111 
the drug core, possibly followed by extensive dissolution/erosion of the hydrated 112 
polymer. The duration of the lag phase is indeed dictated by the physico-chemical 113 
properties of the polymer employed, primarily molecular weight and degree of 114 
hydrophilicity, and by the thickness of the erodible barrier. The manufacturing 115 
technique, which may range from double-compression and spray-coating to hot-116 
processing, can also affect the layer functionality. 117 
In the following sections, oral delivery systems for time-controlled release provided 118 
with an erodible polymer barrier are reviewed, and advances in this particular field are 119 
illustrated with special emphasis on formulation and performance issues. 120 
 121 
Erodible systems manufactured by double-compression 122 
The manufacturing of oral delivery systems provided with erodible coatings dates 123 
back to the early 90s. Until then, the use of such polymers in the manufacturing of solid 124 
dosage forms was tied to tableted hydrophilic matrices for prolonged release. Indeed, 125 
double-compression technique, also known as press-coating, was adopted in all initial 126 
attempts. The first one concerned a three-layer tablet system that was proposed for two-127 
pulse release of drugs [15,16]. Such a system was composed of two conventional drug 128 
(ibuprofen) layers and a high-viscosity HPMC (Methocel
®
 K4M and Methocel
®
 K15M) 129 
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barrier in between. An impermeable ethylcellulose (EC) film covered the lateral area 130 
and one of the bases of the assembly so that the outer surface of a single drug layer was 131 
allowed to interact with solvent upon first contact with the medium. The former dose 132 
fraction was thereby released, whereas the latter was released after a lag phase due to 133 
the hydration and erosion of the polymer barrier. The delay between the release pulses 134 
depended on the viscosity of the polymers employed, and release of the latter dose 135 
fraction was slower. This was ascribed to a less efficient activation of the disintegrant 136 
incorporated within the inner drug layer that was progressively exposed to the aqueous 137 
fluid. The release behavior observed in vitro was reflected in two-peak plasma 138 
concentration curves in healthy volunteers. However, because of its multiple-layer 139 
configuration and the need for a partial coating, the system would involve serious 140 
scalability issues. Therefore, a simpler press-coated formulation was designed, wherein 141 
the polymer, a low-viscosity HPMC (Methocel
®
 K100 LV), covered the entire surface 142 
of the core [17]. The coated system could yield single-pulse release after a lag phase or, 143 
administered in combination with an immediate-release tablet, the repeated release 144 
performance attained from the previous device. In the double compression process, 145 
positioning of the core tablet in the die represented a critical step. However, by correctly 146 
centering it within the polymer powder bed, biconvex tablets with coatings of 147 
homogeneous thickness were obtained. As desired, the in vitro release was delayed for a 148 
reproducible period of time, although leaching of a small percentage of the drug content 149 
prior to the quantitative release phase was inferred from the curves. This was ascribed to 150 
premature outward diffusion of dissolved drug molecules through the swollen polymer 151 
coating. 152 
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A low- and a high-viscosity HPMC grade (Methocel
®
 K100 and Methocel
®
 K4M) 153 
were used, either alone or mixed with each other, as the coating agents of a delivery 154 
system containing ibuprofen, aimed at the chronotherapy of rheumatoid arthritis, or 155 
pseudoephedrine hydrochloride, a water-soluble model drug [18-20]. Increasing the 156 
coating level or the amount of high- vs low-viscosity polymer resulted in longer lag 157 
times and slower in vitro release as well as decreased absorption rates in healthy 158 
volunteers. Sodium alginate, as compared with HPMC, performed as a less effective 159 
barrier-forming polymer. Incorporation of a fraction of the drug dose in the coating 160 
layer changed the release behavior, generally yielding biphasic kinetics that depended 161 
on the composition of the polymeric coat and its drug load. 162 
High-viscosity HPMC (Methocel
®
 K4M, Methocel
®
 K15M and Methocel
®
 K100M) 163 
was employed to prepare a system intended for colonic delivery of the anti-parasitic 164 
drug tinidazole [21]. An enteric coating was applied externally to enable site-selective 165 
release. The lag phase duration and the release rate were markedly affected by the 166 
viscosity grade of the polymer, while hardness of press-coated tablets in a 40-60 N 167 
range did not impact on the relevant performance. Administered to 2 healthy volunteers, 168 
the system was shown to disintegrate in the ascending colon. Methocel
®
 K100M was 169 
also used to coat, at a compression force of 60-80 N, minitablet cores (3 mm in 170 
diameter) intended for immediate or prolonged release of nifedipine [22]. By combining 171 
differing core and coated formulations in a gelatin capsule, a variety of release patterns 172 
were achieved. 173 
Low-viscosity HPMC coatings were applied by an alternative tableting method 174 
(One-Step Dry-Coated, OSDRC) based on the use of a specially modified equipment, 175 
which was previously set up in order to overcome disadvantages typically encountered 176 
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with conventional double-compression technique [23]. These mainly encompass the 177 
need for poorly scalable multiple-step processing, the issue of coat thickness 178 
homogeneity and difficulties in attaining relatively low coating levels. By the OSDRC 179 
method, layers of 0.5-2 mm were obtained, with satisfactory thickness homogeneity and 180 
practically unchanged performance within a 100-200 MPa range of compression 181 
pressure. 182 
High-viscosity HPMC was mixed with polyvinylpyrrolidone (PVP) at different ratios 183 
and applied, by conventional double-compression technique, to minitablet cores 184 
containing solid felodipine/PVP dispersions [24,25]. Mixing with PVP at 30-50% 185 
resulted in improved mucoadhesion of the HPMC coating. The delays prior to a rapid 186 
release of the drug increased in duration with the percentage of HPMC in the 187 
formulation. In vitro delays of more than 10 h were observed with amounts of HPMC at 188 
which mucoadhesive properties were enhanced. The issue of possible inconsistency 189 
between duration of the lag phase and gastrointestinal transit was faced by the design of 190 
a floating pulsatile delivery system aimed at gastro-retention [26]. For this purpose, a 191 
verapamil hydrochloride tablet was first coated with low-viscosity HPMC (Methocel
®
 192 
E5, Methocel
®
 E15 or Methocel
®
 E50), expected to defer the onset of drug release. A 193 
blend of a high-viscosity grade of the polymer (Methocel
®
 K4M) and Carbopol
®
 934P, 194 
which also contained sodium bicarbonate to generate effervescence, was subsequently 195 
applied to a single face of the unit coated with low-viscosity HPMC. The system was 196 
proved able both to delay the onset of release and to float in vitro. Lag time depended 197 
on the viscosity and amount of HPMC in the coating. A ɣ-scintigraphic evaluation in 6 198 
healthy volunteers highlighted the extended gastric residence of the dosage form and 199 
reproducible lag phases before release. In all cases, this occurred in the stomach or 200 
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small intestine. Recently, various grades of HPMC were used to coat tablet cores based 201 
on drugs with differing solubility values [27]. Poorly soluble carbamazepine was 202 
released in a pulsatile fashion after erosion of the coating polymer, and the viscosity 203 
characteristics of the latter strongly impacted on the relevant performance. On the other 204 
hand, more soluble drugs were released in a sigmoidal mode, which was attributed to 205 
their diffusion through the fully hydrated HPMC layer, and a poor influence of the 206 
polymer viscosity was noticed. The outward diffusion of the drug prior to its 207 
quantitative release could be prevented by inserting an enteric film below the erodible 208 
coating. However, this would ultimately impart pH-dependence to the lag phase and 209 
possibly hamper a timely release of the drug for chronotherapeutic purposes. The 210 
amount of HPMC also affected the time and rate of release. 211 
Although HPMC was most widely utilized as a coating agent intended for delaying 212 
dug release, the use of other hydrophilic cellulose derivatives was reported. Particularly, 213 
HPC was the component of a compressed shell that was separately prepared and, once 214 
perforated, manually assembled with a cylindrical core tablet containing isosorbide-5-215 
nitrate [28]. The upper and lower bases of the resulting system were coated with an 216 
impermeable ethylene vinyl acetate copolymer film. Release was deferred until the 217 
polymeric shell was completely eroded or detached. Lag time was affected by the 218 
thickness of such a shell and by the composition of the core. Indeed, replacing 219 
microcrystalline cellulose with lactose shortened the lag phase because of the osmotic 220 
effect exerted by the latter filler. 221 
A diltiazem hydrochloride system based on HPC was prepared by conventional 222 
press-coating [29,30]. As with HPMC, the lag phase duration was modulated either by 223 
increasing/decreasing the amount of coating material applied or by employing HPC, or 224 
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mixtures thereof, with differing viscosity values. Prototype formulations having in vitro 225 
delays of approximately 3 h and 6 h were administered to beagle dogs. A good 226 
agreement was found between in vitro and in vivo data relevant to the former prototype, 227 
whereas lag time in vivo was shorter than in vitro in the latter case. This gap was 228 
reduced when a paddle rotation speed of 150 rpm was set instead of 100 rpm during 229 
release testing. In order to assess its potential for colon delivery, the system having lag 230 
time of 3 h was provided with an enteric HPMCAS film containing a gastric emptying 231 
marker (phenylpropanolamine hydrochloride) [30]. The mean difference between the 232 
time of first appearance in plasma (TFA) of the drug and of the marker molecule was of 233 
about 3 h, which was consistent with the lag time obtained from the pH 6.8 fluid stage 234 
of the in vitro test. HPC was also used in admixture with EC at a weight ratio of 7:1 235 
[31]. The addition of the insoluble polymer aided a faster release of aceclofenac, 236 
intended for the chronotherapy of rheumatic morning pain, after the delay period. The in 237 
vitro performance of press-coated systems based on this blend was proved independent 238 
of various parameters, such as the compression force, paddle rotation speed during 239 
release testing and pH of the medium. Provided with an enteric-coating, the formulation 240 
was administered to rabbits, showing a clear lag phase as opposed to an immediate-241 
release tablet. However, due to variable residence of solid dosage forms in the stomach, 242 
gastroresistance may prevent the anti-inflammatory drug from being released at the time 243 
the disease symptoms occur. 244 
Low-substituted HPC (L-HPC), an insoluble swellable hydrophilic cellulose ether 245 
that is largely used as a disintegrant, was mixed with glyceryl behenate at differing 246 
ratios and subjected to a melt-granulation process [32]. The resulting granules were 247 
applied by double-compression to theophylline tablet cores to give the erodible layer. 248 
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The press-coated tablet was studied in vitro and in beagle dogs, by pharmacokinetic as 249 
well as ɣ-scintigraphic techniques. Lag phases were reproducible in duration and 250 
increased with the amount of glyceryl behenate in the coating formula up to 75%. No 251 
significant differences were found either between in vitro and in vivo lag times, or 252 
between in vivo lag and disintegration times, both in the fasted and fed state. 253 
Press-coated tablets for chronotherapeutic purposes were prepared from HEC 254 
employed as the erodible barrier-forming material [33]. The onset of release of 255 
diltiazem hydrochloride from the core was delayed in vitro as a function of the coating 256 
level and the viscosity grade of HEC. The particle size of the polymer also affected lag 257 
time. Using powders with larger particle dimensions was associated with shorter delay 258 
phases, which was ascribed to the positive effect of a greater porosity on the polymer 259 
hydration process. The role played by HEC viscosity was studied in healthy volunteers 260 
[34]. When this parameter increased, progressively longer lag time (Tlag) and lower 261 
maximum concentration (Cmax) values were observed in the plasma concentration vs 262 
time curves. However, the area under the curve (AUC0-24 h) did not change significantly. 263 
In vitro and in vivo lag times were in agreement. 264 
Besides cellulose derivatives, the use of PEO as a hydrophilic erodible coating agent 265 
was reported. Blended with PEG 6000 at 1:1, it was applied to tablets containing 266 
acetaminophen and differing water soluble excipients, such as PEG 6000, sucrose and 267 
lactose [35]. These were added in order to promote erosion of the core in the distal 268 
intestine, where the press-coated tablets would be intended to release their drug load, 269 
thus possibly counterbalancing the paucity of water of regional fluids. The core erosion 270 
was experimentally quantified and expressed by a purposely introduced parameter, i.e. 271 
the core erosion ratio. In a pharmacokinetic study conducted with fasted beagle dogs, 272 
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greater Cmax and AUC values were obtained from formulations having a higher core 273 
erosion ratio. The amount of PEG 600 vs PEO was raised up to 5:1 in the coating of 274 
nifedipine tablets containing sucrose as an erosion enhancer [36]. In vitro lag times 275 
increased with the percentage of PEO and were aligned with TFA data in beagle dogs. 276 
PEO formed the swelling/erodible upper layer of a press-coated system with an 277 
impermeable cellulose acetate propionate shell covering one of the bases and the lateral 278 
surface [37]. The amount of polymer in the top coating affected both the time and rate 279 
of release of drug molecules with different solubility. Visual monitoring of 280 
morphological changes undergone by the system during in vitro testing highlighted 281 
gradual expansion and erosion of the partial PEO coat until final detachment from the 282 
underlying unit. Used in place of PEO, sodium alginate and sodium 283 
carboxymethylcellulose had less and greater impact on the release performance, 284 
respectively, consistent with their observed swelling/erosion behavior. Guar gum having 285 
ten-fold higher viscosity than PEO also exerted a tighter control of the onset and rate of 286 
release [38]. Increasing the core diameter or adding a soluble filler, such as lactose, to 287 
PEO or guar gum top layers resulted in reduced duration of the lag phase and enhanced 288 
release rate. Differing PEO grades were employed to coat tablets containing solid 289 
dispersions of indomethacin in a novel sucrose fatty acid ester carrier [39]. In vitro lag 290 
time depended on the viscosity and amount of the coating polymer. In 6 healthy 291 
volunteers, press-coated tablet systems with in vitro lag phase of approximately 6 h 292 
brought about delayed appearance of indomethacin in plasma with respect to an 293 
immediate-release commercial product. However, no significant differences were found 294 
in the Cmax and AUC relevant to the two formulations. 295 
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Hydrophilic polymers of natural origin were also proposed as press-coating agents 296 
for time-controlled delivery systems. For instance, powders composed of sodium 297 
alginate and chitosan, forming a polyelectrolyte complex, and of lactose as a filler were 298 
obtained by spray-drying, evaluated for flowability and compaction properties and 299 
finally applied to acetaminophen tablets [40]. Through progressive erosion of the 300 
coating layer, drug release was delayed in pH 6.8 fluid for a time interval that depended 301 
on the chitosan content of the composite powder and on the polymer degree of 302 
deacetylation. A prompt release phase was eventually observed. In pH 1.2 fluid, 303 
acetaminophen was released slowly after longer delays. Prepared for comparison 304 
purposes, physical mixtures of chitosan with spray-dried alginate/chitosan particles and 305 
spray-dried powders composed of lactose and of pre-formed alginate/chitosan complex 306 
failed to provide the desired release pattern. 307 
Blends of the bacterial exopolysaccharide xanthan gum and plant galactomannan 308 
locust bean gum were used in the double-compression coating of the SyncroDose™ 309 
delivery system according to TIMERx
®
 technology [41]. Differing release modes and 310 
lag times were achieved by modifying the concentration and ratio of the two 311 
polysaccharides, performing as synergistically interacting heterodisperse polymers. 312 
 313 
Erodible delivery systems manufactured by spray-coating 314 
The feasibility of coating techniques other than double-compression was explored for 315 
the manufacturing of erodible polymer barriers able to control the onset of drug release. 316 
Particularly, the goals were to establish simpler processing modes, with better industrial 317 
scale-up prospects, exploit conventional production equipment and broaden the range of 318 
viable core formulations (e.g. large tablets, minitablets, granules, pellets, gelatin 319 
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capsules) [17]. Furthermore, some performance issues, strictly connected with the 320 
structure of press-coatings, their relatively high thickness and the relevant homogeneity 321 
limitations, needed to be improved. These primarily involved extended, variable and 322 
poorly flexible lag times, incomplete suppression of drug leakage during the delay 323 
period and impact on the subsequent release phase. Preliminary spray-coating trials 324 
were thus undertaken because such a technique would have allowed continuous and 325 
uniform films to be formed rather than layers of pressed powder, and fluid bed as well 326 
as rotating pan equipment to be utilized instead of specially devised or modified 327 
tableting machines [17,42,43]. In addition, it could in principle be adapted to substrate 328 
dosage forms having diverse size, surface and density characteristics, thereby 329 
circumventing the dimensional and mechanical constraints associated with double-330 
compression. A limited technical background was available on the use of swellable 331 
hydrophilic polymers as film-coating agents, and this mainly concerned application of 332 
low-viscosity grades as thin layers with protective, taste-masking or cosmetic function. 333 
Nonetheless, HPMC with marked viscosity (Methocel
®
 K4M and Methocel
®
 K15M) 334 
appeared potentially suitable for delaying drug release for a time interval on the order of 335 
hours without binding to excessively thick coatings. The polymers were suspended in a 336 
hydro-alcoholic vehicle in order to counteract the thickening effect they exert upon 337 
hydration. The ratio between ethanol and water needed to be adjusted so as to enable 338 
nebulization of the coating suspension at reasonable rates and polymer concentrations 339 
on the one hand, and adequate coalescence of the solid particles on solvent evaporation 340 
on the other. The addition of plasticizing, anti-tacking and binding excipients, such as 341 
PEG 400, talc and PVP, was investigated. The coatings applied to tablets and 342 
minitablets were provided with consistent thickness and smooth surface. Moreover, they 343 
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yielded the desired release pattern. Considering the regulatory issues raised by organic 344 
solvents, the feasibility of aqueous spray-coating by fluid bed was then evaluated using 345 
HPMC having increasing viscosity, namely Methocel
®
 E5, Methocel
®
 E50 and 346 
Methocel
®
 K4M [44-46]. The operating conditions, above all spray rate, inlet air 347 
temperature and polymer concentration in the solutions, required an attentive set-up in 348 
order to overcome major problems of powdering and nozzle clogging as well as lengthy 349 
processing. The viscosity grade of the polymer chiefly affected the process time, 350 
nebulization being possible only with diluted solutions that increased the spraying and 351 
drying duration. From all of the polymers under investigation, coated units with 352 
satisfactory physico-technological characteristics were obtained. The release behavior 353 
was studied by paddle dissolution and modified disintegration apparatus. The latter 354 
proved indeed better suited to prevent sticking of swollen HPMC to the vessels, thus 355 
providing more reliable data. By both testing methods, a prompt release after a lag 356 
phase was highlighted, which depended on the coating level and the polymer viscosity. 357 
Using Methocel
®
 E50 resulted in acceptable process feasibility, ability to delay drug 358 
release and fine-tuning of the lag phase. Moreover, the coating process was shown 359 
robust and potentially scalable. In the case of Methocel
®
 K4M, not only the coating 360 
operations were strongly impaired by the high viscosity of water solutions, but also a 361 
small amount of drug was slowly released from coated units toward the end of the delay 362 
period. This was attributed to the formation of a firm, poorly erodible gel structure 363 
ultimately rupturing with the aid of the inner tablet disintegration upon water influx 364 
[47]. When the Methocel
®
 E50-based coating procedure was applied to hard- and soft-365 
gelatin capsules instead of tablets, the process parameters needed to be adjusted in order 366 
to prevent the sticking and shrinking of the shells [48]. In order to streamline 367 
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manufacturing of Methocel
®
 E50-coated systems, alternative techniques, such as 368 
tangential-spray film-coating and powder-layering carried out by fluid bed 369 
rotogranulator, were attempted. Preliminary studies in volunteers demonstrated that, 370 
irrespective of the core dosage form, delivery systems coated with Methocel
®
 E50 by 371 
aqueous spray-coating were able to defer drug appearance in saliva as a function of the 372 
coating level [45,48]. The in vitro and in vivo lag phases were comparable in duration. 373 
Moreover, when provided with a gastroresistant film, labeled formulations were shown 374 
to consistently break up in the ascending colon. After low-molecular weight drugs, 375 
chosen as models because of their stability characteristics and easy analysis, the 376 
possibility of conveying bovine insulin by this delivery system was explored [48-52]. In 377 
order to increase the chances of preserving integrity of the protein and promoting its 378 
permeation through the intestinal mucosa, enzyme inhibitor and absorption enhancer 379 
adjuvant compounds were incorporated in the formulation. Insulin was proved to 380 
withstand all manufacturing steps, as inferred by assaying the degradation products 381 
mentioned by European Pharmacopoeia, and was released in vitro in a pulsatile mode, 382 
as previously observed with antipyrine and acetaminophen, along with the adjuvants. 383 
The latter were also applied as a separate film enclosed between two Methocel
®
 E50 384 
layers, so that their release would occur earlier than that of the protein drug contained in 385 
the core, and less threatening conditions could be established in vivo beforehand 386 
[53,54]. 387 
When erodible coatings were applied to minitablet cores, relatively larger amounts of 388 
polymer were found necessary than with single units in order to obtain lag times 389 
potentially suitable for chronotherapeutic or colonic release purposes [55-57]. Thus, the 390 
thickness of the resulting film coatings would ultimately fail to comply with the size 391 
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requirements of multiple-unit dosage forms. Besides, depending on the viscosity grade 392 
of the polymer employed, the rate of release at the end of the lag phase would most 393 
likely be reduced. With the aim of overcoming this formulation issue, the external 394 
application of an insoluble, flexible and increasingly leaky film was proposed. Such a 395 
film was mainly intended to slow the uptake of water by the underlying HPMC layer, 396 
and consequently the relevant hydration as well erosion processes, without acting as a 397 
major mechanical constraint to the polymer expansion. Eudragit
®
 NE 30 D was selected 398 
as the film-forming agent, whereas various superdisintegrants, above all Explotab
®
 V17, 399 
were added as especially effective non-conventional pore formers. After tuning the 400 
composition of the outer film and the ration between HPMC and polymethacrylate 401 
coating levels, the desired release performance and dimensional characteristics were 402 
obtained from formulations based on this novel two-layer design. 403 
HPMC barriers derived from coalescence of polymer particles were prepared not 404 
only by spray-coating but also by dipping, which circumvented the technical difficulties 405 
associated with nebulization of highly viscous polymeric solutions [58]. Ethanol/water 406 
mixtures were used to disperse the HPMC powder. Immersion steps, each followed by 407 
manual hot-air drying, were repeated until the tablets had reached the established weight 408 
gain. The latter was related to the lag phase duration. By affecting the structure of the 409 
coat layer, parameters such as the ethanol/water volume ratio, the concentration of the 410 
polymer and the time during which it was allowed to swell in the hydro-organic vehicle 411 
also impacted on the release of nifedipine from the core tablet. 412 
Waxy materials of natural origin, in admixture with a surfactant, were employed as 413 
an alternative to swellable hydrophilic polymers in order to attain erodible barriers for 414 
time-controlled release [59]. Spraying of water dispersions of such lipophilic coating 415 
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agents required that the processing temperature be set at relatively high values (75°C). 416 
The resulting delivery system (Time Clock

) proved suitable for deferring salbutamol 417 
sulfate release in vitro and in healthy volunteers. In both cases, the lag phases were 418 
clearly dependent on the coating level. An agreement between in vitro and in vivo data 419 
was achieved when media having increased viscosity were used for release testing, 420 
which led to longer in vitro delays. The performance of the system in the 421 
gastrointestinal tract was demonstrated not to be influenced by food intake in 6 subjects, 422 
and AUC0-∞ as well as Cmax in the fasted state were consistent with those of an 423 
immediate-release reference product. The Time Clock

 system provided time-based 424 
colonic delivery in humans when in gastro-resistant configuration, as highlighted by ɣ-425 
scintigraphy [60]. This was confirmed in 8 fed volunteers through pharmaco-426 
scintigraphic evaluation of a 5-aminosalicylic acid-containing formulation [61]. 427 
 428 
Erodible delivery systems manufactured by hot-processing techniques 429 
Hot-processing techniques, which enable the production of high-density structures of 430 
any desired form from softened/melted thermoplastic material substrates, are raising 431 
huge interest in every manufacturing area. However, their exploitation in the 432 
pharmaceutical field is still fairly limited despite the enormous potential held [62-65]. It 433 
is only recently that drug delivery applications mainly of hot-melt extrusion (HME), 434 
injection-molding (IM) and three-dimensional (3D) printing by fused deposition 435 
modeling (FDM) have been investigated and reported. Interestingly, the use of such 436 
techniques was proposed for the production of void functional capsule shells 437 
independent of their core units, with considerable prospective advantages from both the 438 
technical and the regulatory point of views [66-68]. In this respect, the feasibility of IM 439 
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in fabrication of erodible shells intended to defer release of their contents was explored 440 
[66]. HPC of various viscosity grades was selected as the capsule-forming polymer 441 
because of the inherent thermoplastic behavior upon heating. A bench-top IM press was 442 
employed, and the design of a specially suited mold was required. Through its use, cap 443 
and body items were obtained within single automated production cycles. In vitro 444 
studies pointed out a rapid release of the model drug after lag times that, composition 445 
being equal, correlated with the thickness of shells in the 300-900 µm range 446 
investigated. By visual inspection of capsule systems immersed in deionized water, it 447 
was inferred that release after the delay phase would be connected with rupturing of the 448 
hemispherical top and bottom ends of the device that were thinner than the cylindrical 449 
region where cap/body portions overlapped. On administration of these prototypes to 3 450 
healthy volunteers, the in vivo lag times calculated from salivary concentration curves 451 
of acetaminophen were found in linear relationship with the in vitro ones [69]. The 452 
design of a novel mold for 600 µm thick units and concomitant setting up of proper 453 
formulation as well as operating parameters were subsequently undertaken [70]. This 454 
allowed faster production cycles to be carried out without adding external or internal 455 
lubricants. The shells obtained showed improved mechanical properties, which would 456 
aid large-scale filling by the equipment used with conventional gelatin capsules, and 457 
less variable thickness that was also closer to the theoretical value. Besides, the issue of 458 
thicker body/cap overlap areas was overcome. As a result, more reproducible release 459 
profiles were attained. The time to shell opening was demonstrated consistent 460 
irrespective of differing types of solid dosage forms conveyed (fine powder, granules, 461 
pellets, solid dispersion). These HPC capsules were successfully subjected to enteric 462 
coating, with no need for sealing the assembled caps and bodies, and then to final curing 463 
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[71]. Such systems fulfilled the requirement of resistance in pH 1.2 medium for 2 h, 464 
while maintaining the original pulsatile release curves when tested in pH 6.8 phosphate 465 
buffer. Accordingly, they appeared potentially suitable for time-dependent colon 466 
delivery, provided that the shell thickness be properly modulated so that duration of the 467 
in vivo lag phase would match the small intestinal transit time. 468 
Capsule shells composed of HPC were lately replicated by FDM 3D printing, starting 469 
from filaments purposely prepared in-house by HME [68]. After assessing the 470 
possibility of attaining hollow structures by the use of FDM and developing the needed 471 
computer-aided design (CAD) files, bodies and caps of the shells were manufactured. 472 
Overall, these exhibited satisfactory physico-technological characteristics and, 473 
assembled into a drug-containing device, the typical lag phase before a rapid and 474 
quantitative release. Upon contact with deionized water, the behavior of capsule shells 475 
fabricated by FDM was comparable with that of analogous molded systems, thus 476 
supporting the real-time prototyping potential of this 3D printing technique and its 477 
possible exploitation in formulation development studies aimed at IM production. 478 
Based on the expertise gained from the manufacturing of functional capsule shells, 479 
cylindrical dosage forms, such as immediate- and prolonged-release polymeric units, 480 
were also fabricated by HME and IM [72,73]. The relevant production via hot-481 
processing was found to offer inherent advantages over the established techniques. 482 
 483 
Conclusions 484 
Drug delivery systems able to incorporate a lag phase of pre-established duration in 485 
their release patterns are a topic of high current interest, primarily in connection with 486 
oral chronotherapy and colon targeting. 487 
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Among the numerous formulation strategies proposed, those based on erodible 488 
polymeric barriers have largely and successfully been exploited. As the main 489 
components of such barriers, swellable/erodible polymers of hydrophilic nature, such as 490 
HPMC and other cellulose derivatives, have especially been used. Indeed, they easily 491 
enable fine-tuning of the release performance in terms of time and also rate through 492 
proper selection of the type and amount of polymer, which will affect the thickness and 493 
viscosity of the layer upon hydration. Erodible barriers intended for time-controlled 494 
release generally consist in coating layers. These may partially or entirely enclose a 495 
drug-containing core thus preventing it from immediately being exposed to aqueous 496 
fluids on administration of the dosage form. Coatings may be applied by differing 497 
techniques and, accordingly, possess diverse structural and functional characteristics. 498 
Apart from coating layers, which are necessarily associated with a specific core 499 
formulation, polymeric barriers in the form of erodible shells have recently been 500 
manufactured by hot-processing, namely via IM and FDM. Because of the great 501 
versatility in terms of design, high innovative content, excellent scale-up prospects and 502 
unique benefits related to a separate development as well as production, these capsule 503 
shells may open up new ways in the field of time-controlled release and, more broadly, 504 
in the oral delivery area.  505 
 506 
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